Study guide

10.2 Cardiovascular Pharmacotherapy

ANCC Family Nurse Practitioner FNP-BC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Application, and Test Day 1.3 Blueprint Weights, TCO Dates, and Study Strategy

2 Assessment Foundations

2.1 Population Health Promotion and Screening 2.2 Comprehensive History and Physical 2.3 Focused History and Physical 2.4 Age-Specific Screening Schedules

3 Function, Risk, and Lifespan Assessment

3.1 Functional Assessment 3.2 Risk Assessment and Social Determinants 3.3 Pediatric Developmental Assessment 3.4 Adolescent, Adult, and Geriatric Assessment

4 Diagnosis Foundations

4.1 Pathogenesis and Pathophysiology 4.2 Diagnostic Test and Procedure Selection 4.3 Interpreting Labs and Imaging 4.4 Normal vs Abnormal Physiologic Change

5 Differential Diagnosis

5.1 Formulating Differential Diagnoses 5.2 Red Flags and Emergency Identification 5.3 Diagnostic Reasoning Traps

6 Prevention and Anticipatory Guidance

6.1 Primary, Secondary, and Tertiary Prevention 6.2 Pediatric and Adolescent Anticipatory Guidance 6.3 Adult and Geriatric Anticipatory Guidance 6.4 Immunization Planning Across the Lifespan

7 Guidelines, Culture, and Evidence

7.1 Crisis, Safety, and End-of-Life Planning 7.2 Clinical Guidelines and Standards of Care 7.3 Culturally and Ethnically Sensitive Practice 7.4 Evidence-Based Research Appraisal

8 Care Plans and Shared Decisions

8.1 Shared Decision-Making 8.2 Multimorbidity and Prioritization 8.3 Referral, Comanagement, and Transitions

9 Pharmacotherapeutics

9.1 Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics 9.2 Interactions, Contraindications, and Monitoring 9.3 Special-Population Prescribing 9.4 High-Alert Medications and Analgesic Safety

10 Cardiovascular Primary Care

10.1 Cardiovascular Diagnosis 10.2 Cardiovascular Pharmacotherapy 10.3 Nonpharmacologic Cardiovascular Management 10.4 Lifespan Cardiovascular Issues

11 Respiratory Primary Care

11.1 Respiratory Diagnosis 11.2 Respiratory Pharmacotherapy 11.3 Lifespan Respiratory Care

12 Endocrine and Metabolic Primary Care

12.1 Diabetes Diagnosis and Monitoring 12.2 Diabetes Pharmacotherapy 12.3 Thyroid and Other Endocrine Disorders 12.4 Obesity and Metabolic Disease

13 Gastrointestinal Primary Care

13.1 Gastrointestinal Diagnosis 13.2 GI Pharmacotherapy and Nutrition 13.3 Lifespan Gastrointestinal Care

14 GU, Renal, and Reproductive Primary Care

14.1 GU and Renal Diagnosis and Management 14.2 Women's Reproductive Health 14.3 Pregnancy and Postpartum Primary Care 14.4 Men's Health and Sexual Function

15 HEENT, Skin, and Musculoskeletal

15.1 HEENT Diagnosis and Management 15.2 Integumentary Diagnosis and Management 15.3 Musculoskeletal Diagnosis 15.4 MSK Procedures and Nonpharmacologic Care

16 Neuro, Psych, Heme, Immune, and Infection

16.1 Neurological Diagnosis and Management 16.2 Psychiatric Diagnosis and Substance Use 16.3 Hematopoietic and Immune Disorders 16.4 Common Infections and Anti-Infectives

17 Clinical Delivery Skills

17.1 Office Procedures and Nonpharmacologic Treatment 17.2 Patient-Specific Education 17.3 Therapeutic Communication 17.4 Comprehensive Documentation

18 Professional Practice

18.1 Legal and Ethical Implications 18.2 Health IT, EHR, and AI Ethics 18.3 Regulatory Guidelines: Reportable Disease and Abuse 18.4 APRN Scope, Standards, and FNP Role

19 Outcome Evaluation

19.1 Ethical and Legal Evaluation Issues 19.2 Pharmacotherapeutic Outcome Monitoring 19.3 Nonpharmacologic Outcome Monitoring 19.4 Clinical Data, PROs, and Treatment Efficacy

20 Follow-Up, Systems, and Exam Strategy

20.1 Follow-Up Intervals and Surveillance 20.2 Treatment Adjustment and Deprescribing 20.3 Resource Management and Care Coordination 20.4 Exam-Day Strategy and TCO Review

10.2 Cardiovascular Pharmacotherapy

Key Takeaways Explain This Topic AI

The 2025 AHA/ACC goal is <130/80 mm Hg for most adults; start medication for every confirmed BP ≥140/90, and start at ≥130/80 if there is clinical CVD, prior stroke, diabetes, CKD, or PREVENT™ 10-year risk ≥7.5%.

If PREVENT™ risk is <7.5% and BP is ≥130/80, use lifestyle for 3–6 months and start medication if the average is still ≥130/80.

First-line therapy is race-neutral: a thiazide-type diuretic, ACE inhibitor, ARB, or dihydropyridine CCB; prefer a single-pill dual-class combination for stage 2. Do not teach 'CCB or thiazide first because the patient is Black' as the 2025 rule, and never combine an ACE inhibitor with an ARB.

High-intensity statins belong in clinical ASCVD, LDL-C ≥190 mg/dL, and many adults 40–75 with diabetes; primary prevention is a PREVENT™ plus shared-decision conversation, not a number you invent.

Aspirin is secondary prevention; dual antiplatelet therapy after a stent is cardiology-owned. DOACs are preferred for most nonvalvular AF; warfarin remains required for a mechanical valve or moderate-to-severe mitral stenosis.

Last updated: August 2026

The current TCO names cardiovascular agents as one of the 13 official drug-agent classes. Domain III Planning asks you to pick a guideline-concordant regimen. Domain IV Implementation asks whether you will sign, refuse, or monitor . This is the pharmacotherapy section. Diagnosis lived in 10.1. Lifestyle lives in 10.3. Pregnancy and frailty change the molecule in 10.4.

2025 blood-pressure treatment: PREVENT™, not the old pooled cohort

The treatment goal is <130/80 mm Hg for most adults . Use the PREVENT™ (Predicting Risk of cardiovascular disease EVENTs) equations for 10-year CVD risk. Do not reach for the retired Pooled Cohort Equations on a 2026 exam item.

Start lifestyle plus medication when the confirmed average is ≥140/90 mm Hg — always. That is stage 2, and you do not wait for a risk score to justify the first tablet.

Start medication at a confirmed average ≥130/80 mm Hg when any of these is true:

  • clinical CVD
  • prior stroke
  • diabetes
  • CKD
  • PREVENT™ 10-year risk ≥7.5%

If the average is ≥130/80 and PREVENT™ risk is <7.5% with none of those conditions, prescribe lifestyle for 3–6 months . If the average is still ≥130/80 , start medication . The 2017 habit of leaving some stage 1 adults untreated indefinitely is not the 2025 rule.

First-line drugs are race-neutral

Without a compelling indication, start a thiazide-type diuretic , an ACE inhibitor , an ARB , or a dihydropyridine calcium-channel blocker . That list is race-neutral . Do not teach "start a CCB or a thiazide first because the patient is Black" as the 2025 first-line rule. PREVENT™ itself dropped race in favor of clinical and social-risk inputs; the drug table followed.

For stage 2 hypertension, prefer a single-pill dual-class combination (two first-line classes in one tablet) to improve adherence and shorten time to control. Do not open with a beta blocker for uncomplicated hypertension. Do not combine an ACE inhibitor with an ARB (or add aliskiren to either) — dual renin-angiotensin blockade raises hyperkalemia and acute kidney injury without an outcome prize in primary care.

  • Situation Preferred CV class Why
  • Uncomplicated HTN Thiazide-type, ACEI, ARB, or DHP-CCB 2025 first-line, race-neutral
  • Stage 2 HTN Single-pill dual-class combo Faster control, better adherence
  • Diabetes or CKD with albuminuria ACE inhibitor or ARB Kidney and CV protection

Post-MI, or HFrEF Evidence-based beta blocker (carvedilol, metoprolol succinate, bisoprolol) Compelling outcome data

  • Resistant HTN or HFrEF Spironolactone (if potassium and GFR allow) Fourth-line resistant HTN; MRA in HFrEF
  • ACEI plus ARB Never Dual RAS blockade

Compelling indications override the open-menu first-line list. Albuminuric CKD and diabetes with albuminuria want an ACE inhibitor or ARB (and usually an SGLT2 inhibitor in contemporary diabetes/CKD care — the RAS blocker is still the CV-class answer). Recheck creatinine and potassium in 1–2 weeks after start or a material dose increase (Section 9.2). Spironolactone is the add-on for resistant hypertension once three agents at optimal doses, including a diuretic, have failed — if eGFR and potassium allow — and it is foundational in HFrEF . Watch the potassium when an ACE inhibitor, an ARB, and spironolactone share a med list.

HFrEF in primary care is not "a little furosemide." Foundational therapy is an ARNI (or ACEI/ARB if an ARNI is not yet possible), an evidence-based beta blocker, a mineralocorticoid-receptor antagonist, and — in current GDMT — an SGLT2 inhibitor, titrated with cardiology when the regimen outruns the FNP's comfort. Loop diuretics treat congestion; they do not replace those mortality-reducing classes.

Statins: intensity by indication, risk by conversation

Teach high-intensity statin therapy as the default in four conceptual boxes, not as a brand-name trivia contest.

  • High-intensity examples Expected LDL-C effect
  • Atorvastatin 40–80 mg About ≥50% LDL-C reduction
  • Rosuvastatin 20–40 mg About ≥50% LDL-C reduction

Start or continue high-intensity (or the maximum tolerated intensity) when there is:

Clinical ASCVD (ACS, revascularization, ischemic stroke/TIA, documented CAD or PAD) — this is secondary prevention.

LDL-C ≥190 mg/dL — treat as possible familial hypercholesterolemia; do not open with a token 10 mg.

Diabetes, age 40–75 — at least moderate intensity; escalate toward high intensity when additional risk is obvious.

Primary prevention — estimate risk with PREVENT™ , talk through benefit, bleeding and diabetes risk, cost, and preference. Do not invent a single magic risk percentage if the stem does not give you a current cholesterol-guideline cutoff. Shared decision is the FNP move; silence is not.

Moderate-intensity examples you should recognize: atorvastatin 10–20 mg, rosuvastatin 5–10 mg, simvastatin 20–40 mg. Do not stack simvastatin or lovastatin with a strong CYP3A4 inhibitor (Section 9.1). Baseline ALT ; recheck CK for unexplained muscle symptoms, not as a calendar ritual in an asymptomatic adult.

Antiplatelets and anticoagulants

Aspirin (typically 81 mg daily) is secondary prevention after ACS, ischemic stroke/TIA, or documented atherosclerotic disease unless it is contraindicated. It is not automatic primary prevention — especially in older adults (Section 6.1). Dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) after a coronary stent is cardiology-owned . The FNP does not stop DAPT after a little epistaxis without calling the interventionalist, and does not extend DAPT forever because "more blood thinner feels safer."

For nonvalvular AF , a DOAC (apixaban, rivaroxaban, dabigatran, or edoxaban) is preferred for most adults who need anticoagulation. Dose-adjust for age, weight, and eGFR using that molecule's label — do not copy one DOAC's cutoffs onto another. Warfarin remains required for a mechanical valve and for moderate-to-severe mitral stenosis . Do not "modernize" those patients onto a DOAC. If you inherit warfarin, you own the INR plan (Section 9.2).

Digoxin toxicity and amiodarone you did not start

You may not start digoxin often. You must recognize toxicity : anorexia, nausea, vomiting, visual change ( yellow-green chromatopsia, halos ), confusion, bradycardia, ventricular ectopy, or a newly "regularized" slow pulse in someone who used to be in AF. Risk explodes with renal impairment , hypokalemia , hypomagnesemia , and drugs that raise digoxin ( amiodarone, verapamil ). Hold the drug, correct electrolytes, check a level when it will change management, and get help for unstable rhythms. Low potassium does not exclude toxicity — it promotes it.

Amiodarone is usually a cardiology prescription that lands on your problem list. If it is already prescribed, you monitor it: TSH and free T4 and LFTs about every 6 months , a chest radiograph at baseline and for new dyspnea or cough, pulmonary function if the lung story changes, and an eye exam for visual symptoms. Counsel photosensitivity and blue-gray skin. When amiodarone starts, cut the warfarin dose (often substantially) and halve digoxin and recut the INR and the digoxin plan — do not discover the interaction after a bleed or a pause.

Vignette. A 58-year-old with diabetes, albuminuria, and confirmed BP 138/84 has a PREVENT™ 10-year risk of 11%. 2025 says start medication now , not a six-month lifestyle-only clock, and an ACE inhibitor or ARB is the compelling class. A 44-year-old with the same BP, no target-organ disease, and PREVENT™ risk 4% gets lifestyle for 3–6 months and a booked recheck — then a first-line tablet if the average is still ≥130/80. A 70-year-old with AF and a mechanical mitral valve leaves on warfarin , not apixaban.

Exam trap. The retired race-based CCB/thiazide-first rule, the retired Pooled Cohort 10% statin-or-BP threshold recited as if it were 2025, ACE-plus-ARB "for extra kidney protection," and stopping DAPT in the primary-care hallway are the items written to fail people who studied an older pocket card.

Loading diagram... 2025 hypertension drug start and first-line pick